Login to Your Account

Clinic Roundup

Monday, December 19, 2011
• Advaxis Inc., of Princeton, N.J., said preliminary data from a Phase II trial of ADXS-HPV, with or without cisplatin, in Indian women with recurrent/refractory cervical cancer, showed no serious adverse events. The primary endpoint is overall survival and, though early in the trial, clinical responses have been seen alone or in combination with chemotherapy and have included one complete reponse and three partial responses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription